Burlington, MA – According to filings with the U.S. Securities and Exchange Commission, RedShift BioAnalytics is raising $20,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Julien Bradley played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About RedShift BioAnalytics
RedShiftBio provides a next-generation infrared technology with advanced data analytics to facilitate better, faster decision making in biopharmaceutical development from discovery to market via the direct measurement of previously undetectable change in protein structural attributes critical to drug product efficacy and quality. Our origins are outside of the Life Sciences, but we are fast learners and listen closely to the needs of our customers. Being outsiders allowed us to see how new technologies from other fields could be combined to better solve problems within the Life Sciences. We developed our Microfluidic Modulation Spectroscopy (MMS) platform in response to a customers request for a better solution, and rather than repurpose outdated tools and methods designed originally for other applications, we started anew, and developed MMS from the ground up specifically with the protein scientist in mind. In 2015, in response to the unique capabilities and potential of MMS, we pivoted our spectroscopy business to focus entirely on bringing innovative analytical solutions to the protein scientist. And so we are changing, too. Our RedShiftBio team now includes talented Life Science veterans, protein scientists and instrumentation engineers. We are financially backed by venture capitalists and Waters Corporation, a leading provider of analytical instrumentation for the life sciences with annual sales of over $2 billion. At RedShiftBio, we develop tools to help protein scientist see more clearly. And that’s definitely change for the better.

To learn more about RedShift BioAnalytics, visit http://redshiftbio.com/

Contact:
Julien Bradley, Chief Executive Officer
781-345-7300
jbradley@redshiftbio.com
https://www.linkedin.com/in/julienbradley/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved